These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 24689365)

  • 21. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.
    Block OK; Rodrigo WW; Quinn M; Jin X; Rose RC; Schlesinger JJ
    Vaccine; 2010 Nov; 28(51):8085-94. PubMed ID: 20959154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pichia pastoris-expressed dengue virus type 2 envelope domain III elicits virus-neutralizing antibodies.
    Batra G; Raut R; Dahiya S; Kamran N; Swaminathan S; Khanna N
    J Virol Methods; 2010 Jul; 167(1):10-6. PubMed ID: 20211204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
    Thomas A; Thiono DJ; Kudlacek ST; Forsberg J; Premkumar L; Tian S; Kuhlman B; de Silva AM; Metz SW
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32611757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a novel DNA SynCon tetravalent dengue vaccine that elicits immune responses against four serotypes.
    Ramanathan MP; Kuo YC; Selling BH; Li Q; Sardesai NY; Kim JJ; Weiner DB
    Vaccine; 2009 Oct; 27(46):6444-53. PubMed ID: 19580892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein.
    Mota J; Acosta M; Argotte R; Figueroa R; Méndez A; Ramos C
    Vaccine; 2005 May; 23(26):3469-76. PubMed ID: 15837370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2.
    Izquierdo A; Valdés I; Gil L; Hermida L; Gutiérrez S; García A; Bernardo L; Pavón A; Guillén G; Guzmán MG
    Antiviral Res; 2012 Jul; 95(1):1-8. PubMed ID: 22554934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Domain III of the envelope protein as a dengue vaccine target.
    Guzman MG; Hermida L; Bernardo L; Ramirez R; Guillén G
    Expert Rev Vaccines; 2010 Feb; 9(2):137-47. PubMed ID: 20109025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy.
    Simmons M; Burgess T; Lynch J; Putnak R
    Virology; 2010 Jan; 396(2):280-8. PubMed ID: 19913867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice.
    Zuest R; Valdes I; Skibinski D; Lin Y; Toh YX; Chan K; Hermida L; Connolly J; Guillen G; Fink K
    Vaccine; 2015 Mar; 33(12):1474-82. PubMed ID: 25659270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes.
    Etemad B; Batra G; Raut R; Dahiya S; Khanam S; Swaminathan S; Khanna N
    Am J Trop Med Hyg; 2008 Sep; 79(3):353-63. PubMed ID: 18784226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity.
    Leng CH; Liu SJ; Tsai JP; Li YS; Chen MY; Liu HH; Lien SP; Yueh A; Hsiao KN; Lai LW; Liu FC; Chong P; Chen HW
    Microbes Infect; 2009 Feb; 11(2):288-95. PubMed ID: 19114121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice.
    Lazo L; Zulueta A; Hermida L; Blanco A; Sánchez J; Valdés I; Gil L; López C; Romero Y; Guzmán MG; Guillén G
    Biotechnol Appl Biochem; 2009 Apr; 52(Pt 4):265-71. PubMed ID: 18636968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
    Jackson LA; Rupp R; Papadimitriou A; Wallace D; Raanan M; Moss KJ
    Vaccine; 2018 Jun; 36(27):3976-3983. PubMed ID: 29789238
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice.
    Bernardo L; Pavón A; Hermida L; Gil L; Valdés I; Cabezas S; Linares R; Alvarez M; Silva R; Guillén G; Nagy E; Schlick P; Guzmán MG
    Vaccine; 2011 Jun; 29(25):4256-63. PubMed ID: 21447316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults.
    Manoff SB; Sausser M; Falk Russell A; Martin J; Radley D; Hyatt D; Roberts CC; Lickliter J; Krishnarajah J; Bett A; Dubey S; Finn T; Coller BA
    Hum Vaccin Immunother; 2019; 15(9):2195-2204. PubMed ID: 30427741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of tetravalent and conserved synthetic peptides vaccines derived from Dengue virus Envelope domain I and II.
    Rocha RP; Livonesi MC; Fumagalli MJ; Rodrigues NF; da Costa LC; Dos Santos MC; de Oliveira Rocha ES; Kroon EG; Malaquias LC; Coelho LF
    Virus Res; 2014 Aug; 188():122-7. PubMed ID: 24768848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells.
    Suphatrakul A; Yasanga T; Keelapang P; Sriburi R; Roytrakul T; Pulmanausahakul R; Utaipat U; Kawilapan Y; Puttikhunt C; Kasinrerk W; Yoksan S; Auewarakul P; Malasit P; Charoensri N; Sittisombut N
    Vaccine; 2015 Oct; 33(42):5613-5622. PubMed ID: 26382602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant vesicular stomatitis virus-based dengue-2 vaccine candidate induces humoral response and protects mice against lethal infection.
    Lauretti F; Chattopadhyay A; de Oliveira França RF; Castro-Jorge L; Rose J; Fonseca BA
    Hum Vaccin Immunother; 2016 Sep; 12(9):2327-33. PubMed ID: 27185081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
    Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
    Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elaboration of tetravalent antibody responses against dengue viruses using a subunit vaccine comprised of a single consensus dengue envelope sequence.
    Sun J; Li M; Wang Y; Hao P; Jin X
    Vaccine; 2017 Nov; 35(46):6308-6320. PubMed ID: 28987441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.